Jeff Davies

Jeff Davies

Auto-generated profile, based on publicly available information

Jeff Davies

Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2020 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
JAJames A. Aries
James A. Aries
JDJeffrey K. Davies
Jeffrey K. Davies
RARebecca L. Auer
Rebecca L. Auer
SHSimon L. Hallam
Simon L. Hallam
SMSilvia Montoto
Silvia Montoto
JRJohn Riches
John Riches

5 November 2012 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
EKEleni Kotsiou
Eleni Kotsiou
JDJeff K. Davies
Jeff K. Davies

4 February 2021 in Blood
Verified
Journal Article
Closed access
PDF file
JBJennifer A. Ball
Jennifer A. Ball
ACAndrew James Clear
Andrew James Clear
JAJames Aries
James Aries
SCSarah Charrot
Sarah Charrot
CBCaroline Besley
Caroline Besley
JDJeff K Davies
Jeff K Davies
Gastrointestinal (GI) graft-versus-host disease (GvHD) is a major barrier in allogeneic hematopoietic stem-cell transplantation (AHST). The metabolite retinoic acid (RA) potentiates GI-GvHD in mice via alloreactive T-cells expressing the RA-receptor-alpha (RARα), but the role of RA-responsive cells in human GI-GvHD remains undefined. We therefore used conventional and novel sequential immunostaining and flow cytometry to scrutinize RA-responsive T-cells in tissues and blood of AHST patients and characterize the impact of RA on human T-cell alloresponses. Expression of RARα by human mononuclear cells was increased after RA exposure. RARαhi mononuclear cells were increased in GI-GvHD tissue, contained more cellular RA-binding proteins, localized with tissue damage and correlated with GvHD severity and mortality. Using a targeted candidate protein approach we predicted the phenotype of RA-responsive T-cells in the context of increased microenvironmental IL-23. Sequential immunostaining confirmed the presence of a population of RARahi CD8 T-cells with the predicted phenotype, co-expressing the effector T-cell transcription factor T-bet and the IL-23-specific receptor. These cells were increased in GI- but not skin-GvHD tissues and were also selectively expanded in GI-GvHD patient blood. Finally, functional approaches demonstrated RA predominantly increased alloreactive GI-tropic RARahi CD8 effector T-cells, including cells with the phenotype identified in vivo. IL-23-rich conditions potentiated this effect by selectively increasing b7 integrin expression on CD8 effector T-cells and reducing CD4 T-cells with a regulatory cell phenotype. In conclusion we have identified a population of RA-responsive effector T-cells with a distinctive phenotype which are selectively expanded in human GI-GvHD and represent a potential new therapeutic target.

29 May 2013 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
JDJeff K. Davies
Jeff K. Davies
DTDavid Taussig
David Taussig
HOHeather Oakervee
Heather Oakervee
MSMatthew Smith
Matthew Smith
SASamir G. Agrawal
Samir G. Agrawal
JGJohn G. Gribben
John G. Gribben
The toxicity burden and long-term anti-leukaemic effect of non-myeloablative (NMA) allogeneic haematopoietic stem-cell transplantation (AHSCT) for acute myeloid leukaemia (AML) and myelodysplasia (MDS) remains undefined. We report the outcome of 56 patients with AML/MDS transplanted from human leucocyte antigen-matched donors using NMA conditioning without T-cell depletion. With a median follow-up of 5 years, treatment-related mortality was 9% and current disease-free survival (CDFS) was 45% (overall) and 55% (patients transplanted in remission). Development of graft-versus-host disease upon withdrawal of post-transplant immunosuppression was associated with less relapse and better CDFS. These data confirm that NMA AHSCT without T-cell depletion is safe and can result in sustained remissions of AML/MDS.

26 October 2017 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
JDJeff K. Davies
Jeff K. Davies
SHSandra Hassan
Sandra Hassan
SSShah‐Jalal Sarker
Shah‐Jalal Sarker
CBCaroline Besley
Caroline Besley
HOHeather Oakervee
Heather Oakervee
JCJamie D. Cavenagh
Jamie D. Cavenagh

13 March 2021 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
AJAmanda Jurgensen‐Rauch
Amanda Jurgensen‐Rauch
SGSuzanne Gibbs
Suzanne Gibbs
MFMaresa Farrell
Maresa Farrell
JAJames Aries
James Aries
MGMarianne Grantham
Marianne Grantham
JSJonathan Sive
Jonathan Sive
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.